File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: An Asian multicentre double-blind randomized placebo controlled study

TitleComparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: An Asian multicentre double-blind randomized placebo controlled study
Authors
Keywords2-Pyridinylmethylsulfinylbenzimidazoles
Amoxicillin - adverse effects - therapeutic use
Duodenal Ulcer - drug therapy
Helicobacter Infections - drug therapy
Double-Blind Method
Issue Date2000
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2000, v. 14 n. 2, p. 217-224 How to Cite?
AbstractBackground: In Asian countries with limited resources, clarithromycin-based triple therapy may not be readily available. There are also few direct comparisons of different regimens in Asia. Aim: To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing. Methods: Fourteen centres in Asia participated in this study. Patients with acute duodenal ulcer who were H. pylori-positive were recruited. They were randomized to receive: (a) lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and metronidazole 500 mg b.d. for 2 weeks (LAM-2 W), or (b) LAM for 1 week and placebo (LAM-1 W), or (c) lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and placebo for 2 weeks (LA-2 W). Upper endoscopy was repeated at week 6 to check for duodenal ulcer healing. Symptoms and side-effects were recorded. Results: A total of 228 patients were recruited, and two patients took less than 50% of the drugs. H. pylori eradication rates (intention-to-treat) were 68 out of 82 (83%) with LAM-2 W, 55 out of 71 (78%) with LAM-1 W and 43 out of 75 (57%) with LA-2 W. There were significant differences (P = 0.001) in eradication rates when comparing either LAM-2 W or LAM-1 W with LA-2 W. The eradication rate in patients with metronidazole resistant H. pylori strains were significantly lower than those with metronidazole sensitive strains (P = 0.0001). The duodenal ulcer healing rates at week 6 were 85%, 85% and 72% in LAM-2 W, LAM-1 W and LA-2 W, respectively (P = 0.065). Side-effects occurred in 13%, 11% and 9% in LAM-2 W, LAM-1 W and LA-2 W, respectively. H. pylori eradication and initial ulcer size were factors affecting duodenal ulcer healing. Conclusions: This Asian multicentre study showed that 1-week lansoprazole-based triple therapy without clarithromycin has similar efficacy in H. pylori eradication and ulcer healing compared with a 2-week regimen. Both triple therapies were significantly better than dual therapy in H. pylori eradication. Therefore, 1-week lansoprazole-based triple therapy is as safe and effective as 2-week therapy in eradication of a pylori infection and healing of duodenal ulcer in these Asian centres.
Persistent Identifierhttp://hdl.handle.net/10722/48624
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorXiao, SDen_HK
dc.contributor.authorHu, FLen_HK
dc.contributor.authorQian, SCen_HK
dc.contributor.authorHuang, NXen_HK
dc.contributor.authorLi, YYen_HK
dc.contributor.authorHu, PJen_HK
dc.contributor.authorDaldiyonoen_HK
dc.contributor.authorManan, Cen_HK
dc.contributor.authorLesmana, Len_HK
dc.contributor.authorCarpio, REen_HK
dc.contributor.authorPerez Jr, JYen_HK
dc.contributor.authorFock, KMen_HK
dc.contributor.authorKachintorn, Uen_HK
dc.contributor.authorPhornphutkul, Ken_HK
dc.contributor.authorKullavanijaya, Pen_HK
dc.contributor.authorHo, Jen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2008-05-22T04:19:21Z-
dc.date.available2008-05-22T04:19:21Z-
dc.date.issued2000en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2000, v. 14 n. 2, p. 217-224en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/48624-
dc.description.abstractBackground: In Asian countries with limited resources, clarithromycin-based triple therapy may not be readily available. There are also few direct comparisons of different regimens in Asia. Aim: To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing. Methods: Fourteen centres in Asia participated in this study. Patients with acute duodenal ulcer who were H. pylori-positive were recruited. They were randomized to receive: (a) lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and metronidazole 500 mg b.d. for 2 weeks (LAM-2 W), or (b) LAM for 1 week and placebo (LAM-1 W), or (c) lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and placebo for 2 weeks (LA-2 W). Upper endoscopy was repeated at week 6 to check for duodenal ulcer healing. Symptoms and side-effects were recorded. Results: A total of 228 patients were recruited, and two patients took less than 50% of the drugs. H. pylori eradication rates (intention-to-treat) were 68 out of 82 (83%) with LAM-2 W, 55 out of 71 (78%) with LAM-1 W and 43 out of 75 (57%) with LA-2 W. There were significant differences (P = 0.001) in eradication rates when comparing either LAM-2 W or LAM-1 W with LA-2 W. The eradication rate in patients with metronidazole resistant H. pylori strains were significantly lower than those with metronidazole sensitive strains (P = 0.0001). The duodenal ulcer healing rates at week 6 were 85%, 85% and 72% in LAM-2 W, LAM-1 W and LA-2 W, respectively (P = 0.065). Side-effects occurred in 13%, 11% and 9% in LAM-2 W, LAM-1 W and LA-2 W, respectively. H. pylori eradication and initial ulcer size were factors affecting duodenal ulcer healing. Conclusions: This Asian multicentre study showed that 1-week lansoprazole-based triple therapy without clarithromycin has similar efficacy in H. pylori eradication and ulcer healing compared with a 2-week regimen. Both triple therapies were significantly better than dual therapy in H. pylori eradication. Therefore, 1-week lansoprazole-based triple therapy is as safe and effective as 2-week therapy in eradication of a pylori infection and healing of duodenal ulcer in these Asian centres.en_HK
dc.format.extent57693 bytes-
dc.format.extent244752 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/pdf-
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.comen_HK
dc.subject2-Pyridinylmethylsulfinylbenzimidazolesen_HK
dc.subjectAmoxicillin - adverse effects - therapeutic useen_HK
dc.subjectDuodenal Ulcer - drug therapyen_HK
dc.subjectHelicobacter Infections - drug therapyen_HK
dc.subjectDouble-Blind Methoden_HK
dc.titleComparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: An Asian multicentre double-blind randomized placebo controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=14&issue=2&spage=217&epage=224&date=2000&atitle=Comparison+of+lansoprazole-based+triple+and+dual+therapy+for+treatment+of+Helicobacter+pylori-related+duodenal+ulcer:+an+Asian+multicenter+double-blind+randomized+placebo+controlled+studyen_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturepostprinten_HK
dc.identifier.doi10.1046/j.1365-2036.2000.00689.xen_HK
dc.identifier.pmid10651663-
dc.identifier.scopuseid_2-s2.0-0033950432en_HK
dc.identifier.hkuros50517-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033950432&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue2en_HK
dc.identifier.spage217en_HK
dc.identifier.epage224en_HK
dc.identifier.isiWOS:000085637900010-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridXiao, SD=12780231400en_HK
dc.identifier.scopusauthoridHu, FL=7202526345en_HK
dc.identifier.scopusauthoridQian, SC=19737868200en_HK
dc.identifier.scopusauthoridHuang, NX=7402533028en_HK
dc.identifier.scopusauthoridLi, YY=7502074529en_HK
dc.identifier.scopusauthoridHu, PJ=7201989582en_HK
dc.identifier.scopusauthoridDaldiyono=7409838621en_HK
dc.identifier.scopusauthoridManan, C=6506149652en_HK
dc.identifier.scopusauthoridLesmana, L=26039273200en_HK
dc.identifier.scopusauthoridCarpio, RE=7004184938en_HK
dc.identifier.scopusauthoridPerez Jr, JY=7403417016en_HK
dc.identifier.scopusauthoridFock, KM=7006721062en_HK
dc.identifier.scopusauthoridKachintorn, U=6602163678en_HK
dc.identifier.scopusauthoridPhornphutkul, K=6603471491en_HK
dc.identifier.scopusauthoridKullavanijaya, P=35546988900en_HK
dc.identifier.scopusauthoridHo, J=7402650284en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats